Remotely Observed Methadone Evaluation II
Remote Observed Methadone Evaluation Phase II (ROME II): Retention and Costs of Care
Sonara Health
100 participants
Dec 24, 2024
INTERVENTIONAL
Conditions
Summary
Methadone is an effective treatment for severe opioid use disorder (OUD), but access is limited due to the requirement of daily observed dosing by most opioid treatment programs (OTPs). Sonara Health designed a HIPAA-compliant web-application called Sonara that features integrated video dosing recording, a tamper-evident seal, and an innovative measurement-based care (MBC) framework called the Opioid Craving Visual Analogue Scale (OC-VAS) to facilitate methadone take-homes while providing evidence of appropriate use and monitoring patient outcomes. Phase II of this SBIR aims to compare Sonara against usual take-homes to assess its impact on retention in care, opioid use, patient outcomes, and costs of care.
Eligibility
Inclusion Criteria2
- Willing to participate in a randomized trial
- Able to complete study instruments and interviews
Exclusion Criteria6
- Less than 18 years of age
- Pregnant or planning to be pregnant
- Currently involved in the criminal justice system
- Serious mental health problems
- Treated with buprenorphine
- Please note: The enrollment target (2.5 randomizations per week over 50 weeks) includes oversampling women and under-represented racial/ethnicity groups (i.e., at least 10 or more individuals per group who identify as Black, Hispanic, and American Indian/Alaskan Native).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Sonara virtual dosing window and engagement platform
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06338280